mometasone sinus implant

Drug Overview

In the clinical specialty of Endocrinology and Otorhinolaryngology, managing chronic mucosal inflammation requires a shift from systemic therapy to localized, high-potency Targeted Therapy. The mometasone sinus implant is a bioabsorbable, drug-eluting Corticosteroid delivery system. It serves as a specialized intervention designed to provide a sustained release of anti-inflammatory medication directly to the sinus mucosa.

• Generic Name: Mometasone furoate
• US Brand Names: Sinuva, Propel, Propel Mini, Propel Contour
• Route of Administration: Sinus Implantation (In-office or surgical placement)
• FDA Approval Status: FDA-approved (2011 for Propel; 2017 for Sinuva)

The mometasone sinus implant is specifically utilized for Chronic rhinosinusitis with nasal polyps. While traditional nasal sprays often fail to reach the deep recesses of the ethmoid or frontal sinuses, this implant ensures the steroid remains in constant contact with the tissue, reducing the need for oral “bursts” of systemic steroids that can disrupt the body’s natural hormonal balance.

What Is It and How Does It Work? (Mechanism of Action)

The mometasone sinus implant functions through a Targeted Therapy delivery model, utilizing a bioabsorbable polymer lattice that slowly dissolves over several weeks.

Molecular and Hormonal Level

1. Sustained Release: Once the implant is expanded within the sinus cavity, it begins a controlled elution of mometasone furoate. Mometasone is a highly lipophilic corticosteroid with high affinity for the glucocorticoid receptor.
2. Anti-Inflammatory Signaling: At the cellular level, mometasone crosses the cell membrane and binds to receptors that move into the nucleus. Here, it inhibits the transcription of genes responsible for producing eosinophilic and lymphocytic inflammatory mediators.
3. Mechanical Scaffolding: Beyond the chemical effect, the physical structure of the implant acts as a temporary “stent,” keeping the sinus ostia (openings) physically open while the medication reduces the swelling of the surrounding mucosa.
4. Hormonal Preservation: By delivering the steroid topically at a micro-gram level over 30 to 90 days, the implant minimizes systemic absorption. This is critical for protecting the Hypothalamic-Pituitary-Adrenal (HPA) axis from the suppression typically caused by repeated courses of oral prednisone.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved use for the mometasone sinus implant is the treatment of chronic rhinosinusitis with nasal polyps in adult patients who have had previous ethmoid sinus surgery.

Other Approved & Off-Label Uses

Within the scope of advanced metabolic and inflammatory care, these implants are used to stabilize the delicate sinus environment.

• Primary Endocrinology and Inflammatory Indications:
  • Post-Surgical Stabilization: Maintaining sinus patency (openness) immediately following a Functional Endoscopic Sinus Surgery (FESS).
  • Recurrent Polyposis: Reducing the size of nasal polyps that have returned after prior surgical removal.
  • Reduction of Adhesions: Preventing the formation of scar tissue (synechiae) that can block sinus drainage.
  • Steroid-Sparing Therapy: Used specifically in diabetic patients or those with osteoporosis who must avoid systemic (oral) corticosteroids due to the risk of hyperglycemia or bone loss.

Dosage and Administration Protocols

The mometasone sinus implant is a medical device procedure and does not follow a traditional “pill” dosing schedule.

Product Name	Drug Amount	Duration of Release	Clinical Setting
Propel	370 mcg	~30 days	Post-surgical (Operating Room)
Sinuva	1,350 mcg	~90 days	In-office (Recurrent polyps)

Important Administration Guidelines:

• Procedure: The implant is placed by an Otolaryngologist (ENT) using endoscopic guidance. For Sinuva, this is often performed under local anesthesia in a clinic setting.
• Absorption: The polymer lattice is bioabsorbable; it does not typically need to be surgically removed. The Sinuva implant is usually removed by a physician after 90 days, whereas Propel dissolves on its own.
• Irrigation: Patients must continue using saline sinus rinses to keep the implant moist and prevent the buildup of crusting, which could impede drug elution.

Warning: Placement and management must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical study data (2020–2026) reinforces the implant as a superior method for maintaining long-term sinus health compared to sprays alone.

• Polyp Reduction: In the RESOLVE II clinical trials, patients treated with the 1,350 mcg implant showed a significant reduction in polyp grade and a 50% decrease in nasal obstruction scores compared to the control group.
• Surgery Prevention: Numerical data shows that use of the implant can reduce the need for repeat surgical intervention by approximately 60% to 70% in patients with recalcitrant (stubborn) polyposis.
• HPA Axis Safety: Research involving 24-hour urinary cortisol testing has confirmed that even the high-dose (1,350 mcg) implant results in no significant suppression of the HPA axis, making it safe for patients with endocrine sensitivities.
• Post-Op Patency: In surgical cohorts, the Propel implant reduced the occurrence of frontal sinus scarring by 40% compared to standard post-operative packing.

Safety Profile and Side Effects

Black Box Warning

The mometasone sinus implant does not have a “Black Box Warning.”

Common Side Effects (>10%)

• Nasal congestion or crusting.
• Mild nosebleeds (epistaxis).
• Upper respiratory tract infections.
• Localized headache or sinus pressure.

Serious Adverse Events

• Implant Migration: The device could move or be prematurely “blown out” of the nose.
• Infection: Rare instances of localized fungal or bacterial sinusitis around the implant site.
• Tissue Granulation: Excessive scar tissue forming in reaction to the polymer (very rare).
• Ocular Changes: Although systemic absorption is low, clinicians monitor for increased intraocular pressure in patients with a history of glaucoma.

Management Strategies

Safety is managed through post-placement endoscopic checks. Patients are instructed not to forcefully blow their nose for the first several days to prevent the implant from dislodging.

Research Areas

Direct Clinical Connections

Active research (2025–2026) is investigating the implant’s interaction with the HPA axis in “high-sensitivity” populations, such as pediatric patients or those with primary adrenal insufficiency. Scientists are confirming that the localized elution is the safest method for delivering steroids to these specific groups.

Generalization

In the field of Targeted Therapy, research is focusing on Novel Delivery Systems that would allow for the elution of different medications, such as antibiotics or biologics (e.g., monoclonal antibodies like dupilumab), directly from the same bioabsorbable scaffold.

Severe Disease & Prevention

Research is exploring the implant’s efficacy in preventing the long-term “remodeling” of sinus tissue. By maintaining an inflammation-free environment for 90 days at a time, researchers aim to determine if the chronic cycle of tissue thickening and polyp growth can be permanently halted.

Disclaimer: This information should be considered exploratory unless supported by definitive clinical evidence. While it represents significant frontiers in medical research, it is not yet applicable to all clinical scenarios or standard of care protocols.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Nasal endoscopy to grade polyp size and a CT scan of the sinuses.
• Organ Function: No specific renal or hepatic requirements due to low systemic absorption.
• Screening: Review of previous surgical history and a check for allergies to mometasone or the bioabsorbable polymer.

Monitoring and Precautions

• Vigilance: Monitoring for “therapeutic escape” (return of symptoms) after the 90-day release period concludes.
• Lifestyle: Medical Nutrition Therapy (MNT) focuses on identifying and avoiding inflammatory food triggers that may worsen mucosal swelling.
• Irrigation Protocol: Use of high-volume, low-pressure saline rinses twice daily to facilitate drug delivery.

“Do’s and Don’ts” List

• DO use your saline rinses exactly as prescribed to keep the implant moist.
• DO report any sudden change in vision or severe eye pain immediately.
• DO inform your doctor if you feel the implant has shifted or fallen out.
• DON’T blow your nose forcefully for at least 48 hours after placement.
• DON’T use other medicated nasal sprays unless specifically instructed by your ENT.
• DON’T ignore signs of a localized infection, such as foul-smelling drainage or fever.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. The mometasone sinus implant is a prescription medical device that must be placed by a board-certified specialist. While systemic absorption is minimal, patients with a history of steroid sensitivity or glaucoma should be monitored closely. Always consult your healthcare provider regarding the risks and benefits of drug-eluting implants for chronic sinusitis.